NCT06904482招募中2 期
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Progression free survival(PFS) at 6 months after transplant
研究概览
简要总结
The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
详细描述
Cord blood (CB) and haplo-identical grafts are valuable alternative graft sources for patients with hematologic malignancies in need of allogeneic transplantation who lack human leukocyte antigen (HLA)-matched adult donors. In Black, Asian, Hispanic populations, the chance of finding a HLA matched donor is 23%, 41%, and 46%, respectively. These graft sources allow for greater HLA difference between donor and recipient, and increase the availability of donors, and therefore transplant, to these populations. Comparative retrospective analyses demonstrate similar results when compared to haplo/cord transplants. In this variant of the standard haplo/cord transplant, investigators will utilize post-transplant cyclophosphamide aGVHD prophylaxis after infusion of the haplo-identical graft and then infuse the CB graft after completion of post-transplant cyclophosphamide. Our hypothesis is that the combination of these two graft sources in which the haplo-identical graft is unmanipulated and the CB graft is infused after post-transplant cyclophosphamide, will be safe and result in effective disease eradication as measured by progression free survival in high risk patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with the following hematologic malignancies:
- •Acute myelogenous leukemia (AML): High-risk AML including:
- •Antecedent hematological disease (e.g., myelodysplasia (MDS))
- •Treatment-related
- •Complete Remission (CR1) with poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
- •Participants must be in CR1, CR2, CR3 or CRi
- •Acute lymphoblastic leukemia (ALL)
- •High-risk CR1 including:
- •Poor-risk cytogenetics (e.g., t(9;22)or 11q23 rearrangements)
- •Presence of minimal disease by flow cytometry or PCR or Clonoseq after 2 or more cycles of chemotherapy
- •No CR within 4 weeks of initial treatment
- •Participants in CR2 or beyond
- •Participants must be in CR1, CR2, CR3, or CRi
- •Myelodysplastic syndromes (MDS), Intermediate, High or Very High Risk by the revised international prognostic scoring system (IPSS-R) or treatment related MDS
- •High-risk lymphoma
- •Age > 18 years
- •Participants without a suitable HLA-matched related or unrelated donor CASE9Z24 Page 17 Version dated 12.16.2025
- •Participants with the following suitable grafts:
- •A 4-8/8 HLA high resolution matched cord blood unit with a cell dose of 1.0x105 CD34 cells/kg.
- •A haplo-identical donor with a goal cell dose of > 4.0x106 CD34cells/kg (minimum 2 x106 CD34 cells/kg)
- •Concurrent Therapy for Extramedullary Leukemia or CNS Lymphoma: Concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated. Such treatment may continue until the planned course is completed. Participants must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement. Maintenance therapy after transplant is allowed.
- •Participants must have the ability to understand and the willingness to sign a written informed consent document
排除标准
- •Participants with inadequate Organ Function as defined by:
- •Creatinine clearance < 40ml/min (Cockcroft-Gault)
- •Bilirubin > 2X institutional upper limit of normal unless Gilbert syndrome
- •AST (SGOT) > 3X institutional upper limit of normal
- •ALT (SGPT) > 3X institutional upper limit of normal
- •Pulmonary function: DLCOc < 60%
- •Cardiac: left ventricular ejection fraction < 40%
- •Participants with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant or breastfeeding women are excluded from this study because chemotherapy involved with RIC have the significant potential for teratogenic or abortifacient effects.
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- •Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
- •Prior autologous stem cell transplant or CAR-T within the preceding 6 months or prior allogeneic transplant.
研究组 & 干预措施
Haplo-Identical / Cord Blood Transplant
Experimental
干预措施: Haplo-Identical / Cord Blood Transplant (Biological)
结局指标
主要结局
Progression free survival(PFS) at 6 months after transplant
时间窗: 6 months after transplant
Kaplan-Meier method will be used to estimate the PFS
次要结局
- Progression free survival at 1 year after transplant(1 year after transplant)
- Progression free survival at 2 years after transplant(2 years after transplant)
- Progression free survival at 3 years after transplant(3 years after transplant)
- Non-relapse mortality at 2 years after transplant(2 years after transplant)
- Non-relapse mortality at 3 years after transplant(3 years after transplant)
- Overall survival(OS) at 1 year after transplant(1 year after transplant)
- Overall survival at 3 years after transplant(3 years after transplant)
- Graft versus host disease relapse free survival at 1 year after transplant(1 year after transplant)
- Graft versus host disease relapse free survival at 2 years after transplant(2 years after transplant)
- Graft versus host disease relapse free survival at 3 years after transplant(3 years after transplant)
- Relapse at 1 year after transplant.(1 year after transplant.)
- Relapse at 2 years after transplant.(2 years after transplant.)
- Non-relapse mortality at 1 year after transplant(1 year after transplant)
- Rate of grade III-IV Acute Graft Versus Host Disease (aGVHD) at 30 days after transplant(30 days after transplant)
- Overall survival at 2 years after transplant(2 years after transplant)
- Relapse at 3 years after transplant.(3 years after transplant.)
- Rate of grade III-IV aGVHD at 100 days after transplant(100 days after transplant)
- Rate of grade III-IV aGVHD at 1 year after transplant(1 year after transplant)
- Rate of grade III-IV aGVHD at 2 years after transplant(2 years after transplant)
- Rate of grade III-IV aGVHD at 6 months after transplant(6 months after transplant)
- Rate of grade III-IV aGVHD at 3 years after transplant(3 years after transplant)
- Rate of grade II-IV aGVHD at 30 days after transplant(30 days after transplant)
- Rate of grade II-IV aGVHD at 100 days after transplant(100 days after transplant)
- Rate of grade II-IV aGVHD at 6 months after transplant(6 months after transplant)
- Rate of grade II-IV aGVHD at 1 year after transplant(1 year after transplant)
- Rate of grade II-IV aGVHD at 2 years after transplant(2 years after transplant)
- Rate of grade II-IV aGVHD at 3 years after transplant(3 years after transplant)
- Rate of severe Chronic Graft Versus Host Disease (cGVHD) at 100 days after transplant.(100 days after transplant)
- Rate of severe cGVHD at 6 months after transplant.(6 months after transplant)
- Rate of severe cGVHD at 1 year after transplant.(1 year after transplant)
- Rate of severe cGVHD at 2 years after transplant.(2 years after transplant)
- Rate of severe cGVHD at 3 years after transplant.(3 years after transplant)
- Rate of moderate cGVHD at 100 days after transplant(100 days after transplant)
- Rate of moderate cGVHD at 6 months after transplant(6 months after transplant)
- Rate of moderate cGVHD at 1 year after transplant(1 year after transplant)
- Rate of moderate cGVHD at 2 years after transplant(2 years after transplant)
- Rate of moderate cGVHD at 3 years after transplant(3 years after transplant)
- Rate of mild cGVHD at 100 days after transplant(100 days after transplant)
- Rate of mild cGVHD at 6 months after transplant(6 months after transplant)
- Rate of mild cGVHD at 1 year after transplant(1 year after transplant)
- Rate of mild cGVHD at 2 years after transplant(2 years after transplant)
- Rate of mild cGVHD at 3 years after transplant(3 years after transplant)
- Rate of serious infections at 1 year after transplant(1 year after transplant)
- Time to neutrophil engraftment.(60 days post treatment)
- Time to platelet engraftment.(60 days post treatment)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic MalignanciesAcute Myelogenous LeukemiaAcute Lymphocytic LeukemiaHodgkin's LymphomaNon-Hodgkin's LymphomaMyelodysplastic SyndromeNCT01745913Weill Medical College of Cornell University2
终止
2 期
Cord Blood Transplantation for Patients With CancerHematological DiseaseNCT01359254University of Chicago1
已完成
3 期
Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCTHematological MalignanciesHematopoietic Stem Cell TransplantationNCT05290545Nanfang Hospital, Southern Medical University314
招募中
1 期
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister DonorRenal Transplant RejectionToleranceKidney TransplantNCT03707262Jeffrey Veale, MD15
招募中
3 期
Haplo-cord HCT vs. Haplo-HCT for T-ALL PatientsAcute T Cell Lymphoblastic LeukemiaHaploidentical Hematopoietic Stem Cell TransplantationCord BloodNCT06381817The First Affiliated Hospital of Soochow University146